
Compass Pathways (NASDAQ:CMPS) has been trading relatively stronger than the S&P 500 recently, in a mostly sideways consolidation pattern compared to the market ETF, which entered into a steep downtrend on Aug. 16.
The psilocybin therapy-focused life sciences company surged 181% between the weeks of May 16 and Aug. 8 and has spent the period since consolidating on decreasing volume on the weekly chart.